Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly by Crinetics

Acromegaly is a rare chronic disease almost always caused by a pituitary adenoma that secretes excess growth hormone, resulting in hypersecretion of IGF-I, predominantly by the liver. Medical therapy is recommended when surgery fails to achieve remission and for patients who are not suitable candidates for surgery. Somatostatin receptor ligands (SRLs), octreotide and lanreotide, administered by injection are first-line medical treatment for acromegaly. However, there are treatment challenges and high burden of treatment with currently available SRLs. These include poor symptom control, specifically worsening of symptoms at the end of each injection cycle, as well as treatment-related injection site reactions and pain associated with monthly injections often administered in a doctor’s office. There is clear need for new reliable treatment options that reduce the burden of care for patients. This program will discuss paltusotine, a novel, investigational once-daily, oral, selectively targeted nonpeptide SRL. Results from the PATHFNDR-1 Phase 3 study in patients with acromegaly switched from injected SRL monotherapy to once-daily oral paltusotine will be presented. Paltusotine is an investigational drug and has not yet been filed or approved for marketing authorization.

This program is sponsored by Crinetics.